It was a pleasure to meet with Prof. Maria-Antonietta D’Agostino (Versailles-Saint-Quentin University and University Hospital Ambroise Paré, Boulogne-Billancourt, France) to discuss her study investigating the responsiveness of the global OMERACT-US enthesitis score in the ULTIMATE clinical study.
The abstract ‘Towards development of an ultrasound enthesitis score in psoriatic arthritis: 24-week results from the phase III randomised ULTIMATE study.‘ (OP0226), was presented at the European Congress of Rheumatology 2021, 2-5 June 2021.
- What are the prevalence, underlying causes and clinical consequences of enthesitis in psoriatic arthritis? (0:38)
- What is the rationale for developing composite enthesitis scores? (2:11)
- Could you give us an overview of the Outcome Measures in Rheumatology Initiative (OMERACT-US) enthesitis scores that you investigated? (3:29)
- Could you tell us a little about the ULTIMATE clinical study and its findings in terms of the OMERACT-US enthesitis score? (5:21)
- What further studies are necessary to validate the OMERACT-US enthesitis scores? (6:42)
Disclosures: Maria-Antonietta D’Agostino has received speaker and/or consultancy fees from Abbvie, BMS, Janseen, Eli-Lilly, Galapagos, and Novartis.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of EULAR 2021 (Virtual).
Share this Video
Related Videos In Psoriatic Arthritis
Maarten Boers, EULAR 2021: Findings from the ULTIMATE Clinical Trial
It was great to talk with Prof. Maarten Boers (VU University Medical Center, Amsterdam, The Netherlands) to discuss the responsiveness and high discriminative validity of GLOESS and clinical outcomes of synovitis in PsA patients treated with secukinumab from the ULTIMATE Trial. The abstract ‘Responsiveness of Ultrasound Synovitis and Clinical Outcomes in Psoriatic Arthritis Treated with […]
Xenofon Baraliakos, EULAR 2021: Findings from the MAXIMISE Study
It was a pleasure to meet with Prof. Xenofon Baraliakos (Ruhr-University Bochum, Herne, Germany) to talk around his presentation on ‘Secukinumab in patients with psoriatic arthritis and axial manifestations: Predictors of response from the double-blind, randomised, phase 3b MAXIMISE trial.‘ (POS0930), which was presented at the European Congress of Rheumatology 2021, 2-5 June 2021. Questions […]
Peter Taylor, EULAR 2021: Highlights from the Congress
We had the pleasure to meet with our Editor-in-Chief, Professor Peter C Taylor (University of Oxford, Oxford, UK) who gave us some of the key highlights from this year’s European Congress of Rheumatology meeting, 2-5 June 2021. Questions What were the highlights of this year’s EULAR meeting? (0:11) Disclosures: Peter C Taylor reports receiving: Research grants […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!